By Raechel Thankam Job July 9 (Reuters) - AstraZeneca's nerve disease drug Wainua, made in partnership with Ionis, ...
By Raechel Thankam Job July 9 (Reuters) - AstraZeneca shares tumbled on Thursday after the company said its nerve disease ...
1don MSN
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
For years, AstraZeneca has commanded one of the richest valuations among large European pharma companies on the assumption that it consistently delivers results.
Astrazeneca (NYSE:AZN) told investors and analysts that it is continuing to embed sustainability into its business strategy ...
Eplontersen’s failure in transthyretin-mediated amyloidosis cardiomyopathy caught Wall Street analysts by surprise and ...
AstraZeneca's stock tumbled after the pharmaceutical company said its Wainua drug failed to meet the primary target in a late-stage clinical trial for heart disease, denting investor hopes for ...
Texas Attorney General Ken Paxton announced Monday that his office has reached a settlement with AstraZeneca Pharmaceuticals ...
July 9 () - AstraZeneca said on Thursday that its drug Wainua, made in partnership with Ionis, failed to meet the ...
Sino Biopharmaceutical will receive $200 million upfront from AstraZeneca, and will be eligible for milestone payments.
Wainua’s ATTR-CM failure is a setback for the AstraZeneca program, but it doesn’t kill the underlying platform value: Ionis ...
Hong Kong-listed Sino Biopharmaceutical said on Wednesday it has granted AstraZeneca the rights to develop a drug designed ...
Sino Biopharmaceutical inks a licensing deal with AstraZeneca for a respiratory drug, with milestones and royalties worth ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results